

Himisha Beltran

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8740927/himisha-beltran-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203
papers

17,087
citations

57
h-index

130
g-index

235
ext. papers

22,404
ext. citations

10.3
avg, IF

6.28
L-index

#	Paper	IF	Citations
203	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022). <i>Advanced Materials</i> , 2022 , 34, 2270014	24	
202	Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102530	2.2	1
201	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 ,	10.2	2
200	Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.. <i>Journal of Pathology</i> , 2022 ,	9.4	1
199	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2022 , 20 Suppl 9, 1-20	0.6	
198	Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2022 , 20 Suppl 9, 2-8	0.6	
197	Future directions for precision oncology in prostate cancer. <i>Prostate</i> , 2022 , 82,	4.2	
196	Epigenetics in prostate cancer: clinical implications. <i>Translational Andrology and Urology</i> , 2021 , 10, 3104-3116	3.16	6
195	Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.. <i>Journal of Biological Chemistry</i> , 2021 , 101556	5.4	1
194	Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
193	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. <i>Nature Communications</i> , 2021 , 12, 6377	17.4	0
192	Epigenetics in prostate cancer: clinical implications. <i>Translational Andrology and Urology</i> , 2021 , 10, 3104-3116	3.16	2
191	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. <i>Advanced Materials</i> , 2021 , e2100096	24	3
190	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021 , 27, 426-433	50.5	25
189	Reprogramming of the FOXA1 cisome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021 , 12, 1979	17.4	11
188	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021 , 5, 44	9.8	6
187	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , 2021 , 4, 785	6.7	0

186	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
185	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , 2021 , 12, 3372	17.4	3
184	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021 , 27, 4923-4936	12.9	6
183	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021 , 79, 722-733	10.2	7
182	Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. <i>Translational Oncology</i> , 2021 , 14, 100944	4.9	2
181	Germline mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. <i>Asian Journal of Andrology</i> , 2021 ,	2.8	0
180	Clinical and Biological Features of Neuroendocrine Prostate Cancer. <i>Current Oncology Reports</i> , 2021 , 23, 15	6.3	17
179	Clinical considerations for the management of androgen indifferent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 623-637	6.2	8
178	Activated ALK Cooperates with N-Myc via Wnt/ECatenin Signaling to Induce Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2021 , 81, 2157-2170	10.1	5
177	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. <i>Npj Precision Oncology</i> , 2021 , 5, 76	9.8	5
176	Therapy considerations in neuroendocrine prostate cancer: what next?. <i>Endocrine-Related Cancer</i> , 2021 , 28, T67-T78	5.7	6
175	A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021 , 5, 74	9.8	4
174	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021 , 30, 47-62	0.9	2
173	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. <i>Nature Cell Biology</i> , 2021 , 23, 1023-1034	23.4	8
172	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021 , 155, 165-171	1.6	4
171	Prostate cancer. <i>Lancet, The</i> , 2021 , 398, 1075-1090	40	28
170	The treatment landscape of metastatic prostate cancer. <i>Cancer Letters</i> , 2021 , 519, 20-29	9.9	6
169	Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021 , 12, 5775	17.4	6

168	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021 , 258-259, 61-68	2.3	0
167	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.. <i>Nature Communications</i> , 2021 , 12, 7349	17.4	10
166	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020 , 3, e2021692	10.4	19
165	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , 2020 , 11, 5549	17.4	31
164	Small extracellular vesicles modulated by $\alpha 5 \beta 1$ integrin induce neuroendocrine differentiation in recipient cancer cells. <i>Journal of Extracellular Vesicles</i> , 2020 , 9, 1761072	16.4	15
163	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2798-2811	2.2	80
162	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1157-1164	6.1	23
161	PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. <i>Molecular Oncology</i> , 2020 , 14, 974-990	7.9	9
160	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. <i>Nature Communications</i> , 2020 , 11, 384	17.4	37
159	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
158	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , 2020 , 130, 1653-1668	15.9	56
157	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020 , 126, 1407-1412	6.4	4
156	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1474-1494	2.2	66
155	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020 , 1, 1041-1053	15.4	18
154	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , 2020 , 11, 6195	17.4	6
153	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3042-3050	2.2	17
152	PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6839-6851	12.9	22
151	Towards precision oncology in advanced prostate cancer. <i>Nature Reviews Urology</i> , 2019 , 16, 645-654	5.5	72

150	Clinical features of neuroendocrine prostate cancer. <i>European Journal of Cancer</i> , 2019 , 121, 7-18	7.5	79
149	Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	8
148	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15
147	The application of precision medicine in diagnosing familial Mediterranean fever. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2091-2093	1.9	
146	ONECUT2 is a driver of neuroendocrine prostate cancer. <i>Nature Communications</i> , 2019 , 10, 278	17.4	72
145	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 11428-11436	11.5	383
144	Retinoblastoma Loss in Cancer: Casting a Wider Net. <i>Clinical Cancer Research</i> , 2019 , 25, 4199-4201	12.9	3
143	Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 2561-2569	6.4	58
142	Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. <i>EBioMedicine</i> , 2019 , 43, 114-126	8.8	24
141	Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. <i>Gynecologic Oncology Reports</i> , 2019 , 28, 54-57	1.3	5
140	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	56
139	Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. <i>Journal of Oncology Practice</i> , 2019 , 15, 343-345	3.1	1
138	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. <i>Cancer Cell</i> , 2019 , 35, 603-617.e8	24.3	29
137	Biological Evolution of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 147-154	5.1	34
136	Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	33
135	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 16987-16996	11.5	6
134	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019 , 25, 6916-6924	12.9	94
133	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. <i>Nature Communications</i> , 2019 , 10, 2977	17.4	71

132	Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. <i>OncolImmunology</i> , 2019 , 8, e1670019	7.2	24
131	N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 3924-3940	15.9	55
130	Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5008-5008	2.2	21
129	Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5018-5018	2.2	3
128	CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5079-5079	2.2	7
127	First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 260-260	2.2	1
126	Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 266-266	2.2	1
125	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 272-272	2.2	5
124	Value of serum neuroendocrine markers in evaluation of neuroendocrine prostate cancer: A validation study using metastatic biopsies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 278-278	2.2	1
123	The genomic landscape of metastatic clear cell renal cell carcinoma (ccRCC) after treatment with systemic therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 675-675	2.2	
122	Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS339-TPS339	2.2	
121	Somatic alterations in a seven-gene DDR gene panel predicts platinum sensitivity in advanced prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 283-283	2.2	
120	SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5065-5065	2.2	
119	Increased Serine and One-Carbon Pathway Metabolism by PKC δ Deficiency Promotes Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2019 , 35, 385-400.e9	24.3	79
118	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019 , 2, 405-412	6.7	8
117	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , 2019 , 25, 43-51	12.9	110
116	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 584-590	4	4
115	Cellular plasticity and the neuroendocrine phenotype in prostate cancer. <i>Nature Reviews Urology</i> , 2018 , 15, 271-286	5.5	153

114	Rapid autopsy of a patient with recurrent anaplastic ependymoma. <i>Palliative and Supportive Care</i> , 2018 , 16, 238-242	2.5	2
113	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018 , 73, 687-693	10.2	70
112	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. <i>Cancer</i> , 2018 , 124, 1008-1015	6.4	24
111	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 645-651	36.3	380
110	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
109	Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. <i>Journal of Pathology</i> , 2018 , 246, 244-253	9.4	21
108	Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. <i>Nature</i> , 2018 , 560, 499-503	50.4	277
107	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , 2018 , 9, 2404	17.4	149
106	Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS399-TPS399	2.2	14
105	CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. <i>AMIA Summits on Translational Science Proceedings</i> , 2018 , 2017, 168-177	1.1	2
104	Detection of germline deleterious mutations in prostate cancer patients with use of a validated 30-gene sequencing assay.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 223-223	2.2	
103	Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 218-218	2.2	
102	Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17072-e17072	2.2	
101	Risk of venous thromboembolism, survival, and expression of procoagulant genes in neuroendocrine versus castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17039-e17039	2.2	
100	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 1435-1435	2.2	1
99	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2492-2503	2.2	271
98	BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	2
97	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4441-4453	15.9	84

96	CD38 is methylated in prostate cancer and regulates extracellular NAD. <i>Cancer & Metabolism</i> , 2018 , 6, 13	5.4	18
95	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018 , 8, 15442	4.9	14
94	Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. <i>Nature Communications</i> , 2018 , 9, 3600	17.4	60
93	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. <i>GigaScience</i> , 2018 , 7,	7.6	35
92	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. <i>European Urology</i> , 2017 , 71, 68-78	10.2	105
91	SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. <i>Science</i> , 2017 , 355, 84-88	33.3	491
90	Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. <i>Nature Biotechnology</i> , 2017 , 35, 577-582	44.5	137
89	Emerging Variants of Castration-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2017 , 19, 32	6.3	86
88	Personalized and Cancer Models to Guide Precision Medicine. <i>Cancer Discovery</i> , 2017 , 7, 462-477	24.4	477
87	Prostate cancer in 2016: Improved outcomes and precision medicine come within reach. <i>Nature Reviews Urology</i> , 2017 , 14, 71-72	5.5	3
86	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	23
85	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017 , 23, 6802-6811 ^{12.9}	12.9	50
84	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. <i>Cancer Cell</i> , 2017 , 32, 792-806.e7	24.3	39
83	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. <i>Journal of Physical Education and Sports Management</i> , 2017 , 3,	2.8	15
82	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. <i>Cancer Discovery</i> , 2017 , 7, 54-71	24.4	173
81	Biology and evolution of poorly differentiated neuroendocrine tumors. <i>Nature Medicine</i> , 2017 , 23, 1-10	50.5	109
80	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 358-369	7.1	3
79	Whole exome sequencing (WES) of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer (NEPC) informs tumor heterogeneity.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5011-5011	2.2	10

78	Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5029-5029	2.2	3
77	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 358-369	7.1	4
76	On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. <i>Anticancer Research</i> , 2017 , 37, 1569-1573	2.3	5
75	Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 299-299	2.2	
74	Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5062-5062	2.2	1
73	Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5093-TPS5093	2.2	
72	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016 , 48, 1490-1499	36.3	161
71	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. <i>Npj Genomic Medicine</i> , 2016 , 1,	6.2	51
70	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1510-9	12.9	96
69	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016 , 22, 298-305	50.5	775
68	Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5009-5009	2.2	1
67	Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5019-5019	2.2	13
66	Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5022-5022	2.2	5
65	Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 354-354	2.2	3
64	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 36, 131-141	7.1	10
63	Integrated whole exome and RNA sequencing to reveal distinct genomic and transcriptomic landscape of upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 379-379	2.2	
62	Fractionated dose radiolabeled antiProstate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 205-205	2.2	
61	Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 268-268	2.2	

60	Impact of therapy on gene expression in high-risk prostate cancer (PCA) treated with neoadjuvant docetaxel and androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8-8	2.2	
59	Synthetic lethality and beyond. <i>Science Translational Medicine</i> , 2016 , 8, 365ec182	17.5	
58	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, 131-41	7.1	18
57	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 443-53	59.2	791
56	An emerging role for cytopathology in precision oncology. <i>Cancer Cytopathology</i> , 2016 , 124, 167-73	3.9	14
55	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2016 , 30, 563-577	24.3	256
54	Prostate cancer: Inpatient heterogeneity in prostate cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 430-1	5.5	14
53	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. <i>Cell Reports</i> , 2015 , 12, 922-36	10.6	155
52	The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 92-103	7.1	30
51	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
50	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. <i>JAMA Oncology</i> , 2015 , 1, 466-74	13.4	207
49	Whole exome sequencing to reveal chemotherapy-driven evolution of platinum-resistant metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4513-4513	2.2	1
48	Defining a molecular subclass of treatment resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5004-5004	2.2	3
47	Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 194-194	2.2	1
46	Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 197-197	2.2	2
45	CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. <i>Oncotarget</i> , 2015 , 6, 11994-2008	3.3	15
44	Outcomes of preoperative chemotherapy in bladder cancer patients including node-positive disease.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 370-370	2.2	
43	Precision medicine program for whole-exome sequencing (WES) provides new insight on platinum sensitivity in advanced prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 158-158	2.2	1

42	Clonal heterogeneity in platinum-resistant metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 290-290	2.2	
41	Effect of prostate-specific membrane antigen (PSMA) radioimmunotherapy on circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 199-199	2.2	
40	Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. <i>Human Pathology</i> , 2014 , 45, 2136-43	3.7	22
39	Organoid cultures derived from patients with advanced prostate cancer. <i>Cell</i> , 2014 , 159, 176-187	56.2	847
38	The many faces of neuroendocrine differentiation in prostate cancer progression. <i>Frontiers in Oncology</i> , 2014 , 4, 60	5.3	155
37	Aggressive variants of castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2846-50	12.9	245
36	High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. <i>Cancer Research</i> , 2014 , 74, 1272-83	10.1	250
35	Unraveling the clonal hierarchy of somatic genomic aberrations. <i>Genome Biology</i> , 2014 , 15, 439	18.3	61
34	ERG induces taxane resistance in castration-resistant prostate cancer. <i>Nature Communications</i> , 2014 , 5, 5548	17.4	81
33	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014 , 5, 5383	17.4	432
32	The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential. <i>Molecular Cancer Research</i> , 2014 , 12, 815-22	6.6	89
31	Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 756-67	6.7	305
30	Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5064-5064	2.2	7
29	Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib. <i>Asian Journal of Andrology</i> , 2014 , 16, 568-9	2.8	1
28	Epigenomic alterations in localized and advanced prostate cancer. <i>Neoplasia</i> , 2013 , 15, 373-83	6.4	59
27	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. <i>Nature Biotechnology</i> , 2013 , 31, 1023-31	44.5	1353
26	Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. <i>Neoplasia</i> , 2013 , 15, 761-72	6.4	39
25	Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. <i>Neoplasia</i> , 2013 , 15, 1-10	6.4	165

24	Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. <i>European Urology</i> , 2013 , 63, 920-6	10.2	313
23	Punctuated evolution of prostate cancer genomes. <i>Cell</i> , 2013 , 153, 666-77	56.2	862
22	New strategies in prostate cancer: translating genomics into the clinic. <i>Clinical Cancer Research</i> , 2013 , 19, 517-23	12.9	47
21	DNA mismatch repair in prostate cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1782-4	2.2	9
20	Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. <i>Cancer Research</i> , 2013 , 73, 1232-44	10.1	137
19	A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS5096-TPS5096	2.2	4
18	Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 121-121	2.2	1
17	Association of CTCAE v4 grading of hypertension with toxicity in patients with renal cancer receiving vascular endothelial growth factor (VEGF)-targeting agents.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 447-447	2.2	3
16	Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15600-e15600	2.2	1
15	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. <i>Journal of Pathology</i> , 2012 , 227, 286-97	9.4	142
14	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 775-83	6.1	30
13	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 6686-91	11.5	42
12	Challenges in recognizing treatment-related neuroendocrine prostate cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, e386-9	2.2	146
11	Prospective analysis of prostate cancer (PC) circulating tumor cells (CTCs) to predict response to docetaxel (DOC) chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 100-100	2.2	3
10	Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 190-190	2.2	
9	Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 120-120	2.2	
8	Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 110-110	2.2	
7	Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4649-4649	2.2	

6	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , 2011 , 1, 487-95	24.4	550
5	New therapies for castration-resistant prostate cancer: efficacy and safety. <i>European Urology</i> , 2011 , 60, 279-90	10.2	111
4	Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2011 , 13, 785-6	2.8	1
3	Primary squamous cell carcinoma of the urinary bladder presenting as peritoneal carcinomatosis. <i>Advances in Urology</i> , 2010 , 179250	1.6	8
2	Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. <i>Cancer</i> , 2010 , 116, 1075-83	6.4	109
1	Discovery and reporting of clinically-relevant germline variants in advanced cancer patients assessed using whole-exome sequencing		2